The lung and pancreatic cancer treatment landscapes are evolving with the introduction of innovative immunotherapies and diagnostic tools. Ivonescimab, a PD-1/VEGF bispecific antibody, gained approval in China for non-small-cell lung cancer, coupling immune checkpoint blockade with anti-angiogenic effects. In the US, tarlatamab, a bispecific T cell engager targeting DLL3, received authorization for small-cell lung cancer. Meanwhile, a collaborative study led by Agenus and Noetik employs AI-based virtual cell models to identify predictive biomarkers for immuno-oncology agents, potentially improving therapeutic targeting and efficacy.